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rial ligands like LPS can play an important role in modulating 
the immune response of primary human immune cells to-
wards IAV infection, which may then have important conse-
quences for the development of the host’s adaptive immune 
response.  Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Influenza A virus (IAV) is a negative-sense RNA virus 
of the Orthomyxoviridae  family that causes both season-
al epidemics as well as global pandemics. Every year, on 
average, influenza virus infects 5–15% of the world’s pop-
ulation, resulting in approximately 500,000 deaths  [1] . In 
addition, infection with IAV creates a window of suscep-
tibility to secondary bacterial infections. In recent years, 
it has become evident that viral-bacterial interactions are 
not uni-directional, and just as IAV can facilitate bacte-
 Key Words 
 Antiviral response · CD8+ T cells · Human macrophages · 
Influenza virus · Lipopolysaccharides 
 Abstract 
 It is well established that infection with influenza A virus 
(IAV) facilitates secondary bacterial disease. However, there 
is a growing body of evidence that the microbial context in 
which IAV infection occurs can affect both innate and adap-
tive responses to the virus. To date, these studies have been 
restricted to murine models of disease and the relevance of 
these findings in primary human cells remains to be eluci-
dated. Here, we show that pre-stimulation of primary human 
monocyte-derived macrophages (MDMs) with the bacterial 
ligand lipopolysaccharide (LPS) reduces the ability of IAV to 
infect these cells. The inhibition of IAV infection was associ-
ated with a reduced transcription of viral RNA and the ability 
of LPS to induce an anti-viral/type I interferon response in 
human MDMs. We demonstrated that this reduced rate of 
viral infection is associated with a reduced ability to present 
a model antigen to autologous CD8+ T cells. Taken together, 
these data provide the first evidence that exposure to bacte-
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rial disease, so too may exposure to certain bacterial spe-
cies affect the pathogenesis of IAV  [2] . 
 Historically, bacteria have been thought to aid IAV in-
fection via the production of proteases that cleave the vi-
ral haemagglutinin into its active form  [3, 4] . Alterna-
tively, bacterial toxins may suppress key components of 
the anti-viral response such that the pathogenicity of IAV 
is increased  [5] . Recent studies have suggested that the 
bacterial species that constitute an individual’s normal 
flora represent a key component of the host defence 
against IAV  [6, 7] . Ichinohe et al.  [6] demonstrated that 
commensal flora provide the first signal for inflamma-
some activation, which is necessary for dendritic cell 
(DC) migration and the development of an effective 
adaptive immune response against IAV. Accordingly, an-
tibiotic-treated mice (whose normal flora had been re-
duced) displayed increased susceptibility to IAV infec-
tion. Abt et al.  [7] also demonstrated that antibiotic-treat-
ed mice displayed increased susceptibility to IAV 
infection, which was characterised by increased viral rep-
lication, decreased CD8+ T cell activation/migration and 
a suppressed humoral response. This impaired immune 
response was attributed to the inability of macrophages 
from antibiotic-treated mice to mediate an appropriate 
anti-viral response and respond to type I interferons 
(IFNs). Consistent with these findings, pre-stimulation of 
certain toll-like receptors (TLRs) with bacterial-patho-
gen-associated molecular patterns (PAMPs) protected 
mice from infection with influenza virus  [8, 9] . Specifi-
cally, treatment of mice with the TLR4 agonist lipopoly-
saccharide (LPS) protected against a lethal infection with 
A/Vietnam/1203/04(H5N1), whilst treatment with the 
TLR2 agonist mycoplasma lipoprotein did not  [8] , poten-
tially due to the induction of type I IFNs following TLR4 
rather than TLR2 stimulation. 
 Taken together, the above studies suggest that sub-
stantive crosstalk exists between bacterial PAMP signal-
ling pathways and the induction of both innate and adap-
tive anti-viral immunity. However, whilst these studies 
have highlighted the important role that bacterial species 
and ligands play in modulating the pathogenesis of IAV, 
it remains unclear how far these findings can be extrapo-
lated from murine models to human infections. Here, we 
seek to address the effect of pre-exposure to specific bac-
terial ligands on IAV infection of primary human macro-
phages. Macrophages were chosen as the model cell type 
because of their presence in the nasal cavity  [10] , which 
represents the first site of infection for IAV and is an area 
of high bacterial density and diversity. Macrophages play 
an integral role in survival of IAV infection  [11] . More-
over, macrophages are long-lived antigen-presenting 
cells (APCs) and are crucial for tissue homeostasis  [12] . 
Training of these cell types by bacterial ligands in the na-
sopharyngeal mucosa could therefore have important 
consequences on the immune response towards a viral 
infection. 
 We show that pre-stimulation of human monocyte-
derived macrophages (MDMs) with LPS inhibits IAV 
replication, which was associated with the induction of a 
strong anti-viral response and reduced viral transcrip-
tion. Importantly, we show that LPS-stimulated macro-
phages are less able to present a model antigen to autolo-
gous CD8+ T cells upon IAV infection. Thus, we provide 
the first evidence using primary human cells that expo-
sure to bacterial ligands may affect the adaptive immune 
response to IAV. 
 Materials and Methods 
 Virus Strains  
 Influenza virus strains A/PR8/8/34 (PR8/34; H1N1), A/HKx31 
(HKx31; H3N2) or A/PR8-GFP/8/34 (GFP-PR8/34; H1N1)  [13] 
were used to model infection with IAV. Virus stocks were prepared 
in embryonated eggs and titres of infectious virus were determined 
by three independent plaque assays on Madin-Darby canine kid-
ney (MDCK) cells  [14] . Where relevant, PR8/34 was purified by 
rate zonal sedimentation on 25–80% w/v sucrose gradients as de-
scribed  [15] . Green fluorescent protein (GFP)-labeled RSV A2 
(rgRSV30)  [16] was cultured on HeLa cells as described previous-
ly  [17] . Virus concentration was determined by titration on HeLa 
cells. Briefly, HeLa cells (80–90% confluent) were infected with 
fivefold viral dilutions for 20–22 h. Virus titre was determined by 
counting wells with  ≥ 10 and  ≤ 100 infected cells/view (CKX41 mi-
croscope; Olympus, Tokyo, Japan) where each data point was the 
average of an experimental duplicate. 
 Isolation and Infection of Macrophages 
 Human peripheral blood mononuclear cells (PBMCs) were 
isolated from blood obtained from anonymised buffy coats of 
healthy donors (Sanquin, The Netherlands, or Australian Red 
Cross, Australia) or from healthy volunteers upon informed writ-
ten consent. Where relevant, experiments were approved by the 
Ethics Committee of the University of Melbourne, Australia. 
PMBCs were isolated from buffy coats by density gradient cen-
trifugation (Lymphoprep; Axis-Shield, Norway), essentially as de-
scribed previously  [17] . PBMCs were then washed, resuspended in 
10% DMSO (v/v) with heat-inactivated fetal calf serum (FCS) and 
frozen in liquid nitrogen until use. Alternatively, washed PBMCs 
were used fresh and monocytes were isolated by adherence to plas-
tic in the presence of 2% human serum (Sigma, USA) and allowed 
to differentiate for 6 days in RPMI-1640 medium supplemented 
with 10% heat-inactivated FCS. MDMs were washed and stimu-
lated with the relevant bacterial ligand ( table 1 ). At the selected 
time point after stimulation, MDMs were washed and infected 
with IAV or RSV (multiplicity of infection, MOI, 0.01 and 1, re-
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spectively) for 1 h at 37  °  C. Virus was then removed and cells were 
incubated for 16 h in RPMI-1640 medium supplemented with 10% 
heat-inactivated FCS. Cells were then fixed and analysed on a 
 LSRII or FACSCanto flow cytometer (BD Biosciences, USA) with 
FACSDiva software (BD Biosciences). Collected samples were an-
alysed with FLOWJO, version 8.8.7 (TreeStar, Inc., USA) where 
IAV infection was determined as the percentage of single cells that 
were GFP positive.
 Virus Adhesion and Internalisation  
 Purified PR8/34 (1.75 or 0.88 μg) was added to 2 × 10 5 MDMs 
24 h after LPS or mock stimulation. Virus was adhered to cells for 
a pre-determined period of time at either 4 or 37  °  C. For uninfect-
ed controls, PBS was added in place of purified PR8/34. Cells 
were  then washed and virus particles on the cell surface were 
stained with monoclonal antibody E2.6 (αPR8/34-haemagglutinin; 
kindly provided by Prof. Lorena Brown, The University of Mel-
bourne). Following washing, cells were stained with fluorescein 
isothiocyanate (FITC) goat-anti-mouse IgG (Millipore, USA). 
Cells were then fixed and analysed on a FACSCantoII with 
 FACSDiva software (BD Biosciences). Collected samples were an-
alysed with FLOWJO, version 8.8.7 (TreeStar, Inc.) where IAV in-
fection was determined as the percentage of single cells that were 
FITC positive.
 Staining of IAV-Infected Cells 
 Infection of cells with a non-GFP-labelled IAV strain was as-
sessed by staining with an anti-nucleoprotein monoclonal anti-
body (MP3.10G2.IC7; WHO Collaborating Centre for Reference 
and Research on Influenza) following cell permeabilisation with 
80% (v/v) acetone. Cells were subsequently stained with FITC goat 
anti-mouse IgG (Millipore), fixed and measured on a  FACSCantoII 
with FACSDiva software (BD Biosciences). Collected samples 
were analysed with FLOWJO, version 8.8.7 (TreeStar) where IAV 
infection was determined as the percentage of single cells that were 
FITC positive.
 RNA Extraction, cDNA Synthesis and Quantitative RT-PCR 
 Total RNA was extracted using the RNeasy kit (Qiagen, USA), 
genomic DNA was removed using TurboDNase (Ambion, USA) 
and cDNA was synthesized using SuperScript TM reverse transcrip-
tase (Invitrogen), according to the manufacturer’s instructions. 
cDNA for viral mRNA quantification was synthesised using 
oligo(dT) 20 (Roche, USA), cDNA for viral RNA (vRNA) quantifi-
cation was synthesised using the Uni12 primer  [18, 19] and cDNA 
for host gene expression using both oligo(dT) 20 (Roche) and ran-
dom hexamers. Quantitative PCR measurements for IFN-β 
(NM_002176.2), IFN-γ (NM_000619.2), RIG-I (NM_014314.3), 
IFIT1 (NM_001548.3), TNF-α (NM_000594.2) and GAPDH 
(NM_002046.4) were performed using commercially available 
TaqMan gene expression assays (Applied Biosystems, USA). The 
PCR conditions were as follows: 10 min at 95   °   C, followed by 40 
cycles of 15 s at 95   °   C and 60 s at 60   °   C. Mean relative mRNA ex-
pression from two replicate measurements was normalised to 
GAPDH expression and calculated using the ΔΔCT method. Al-
ternatively, quantitative PCR was performed using SYBR green 
(Quantance; SensiMix, UK) and primers targeting the matrix gene 
of PR8/34 (forward: 5 ′ -AAGACCAATCCTGTCACCTCTGA-3 ′ 
and reverse: 5 ′ -TCCTCGCTCACTGGGCA-3 ′ ) on the Stratagene 
Mx3005 quantitative PCR thermocycler (Agilent Technologies, 
USA) as described previously  [19] . Cycling conditions were as fol-
lows: 95  °  C for 15 min followed by 38 cycles of 95  °  C for 15 s, 56  °  C 
for 60 s and 72  °  C for 30 s. In each plate, cDNA levels were calcu-
lated using a standard curve created from tenfold dilutions on plas-
mid DNA (pHW2000 containing the PR8/34 matrix gene).
 Microarray Analysis  
 Four independent samples (each derived from a different do-
nor) were used for each condition and were analysed using Af-
fymetrix human ST 1.0 exon arrays. RNA quality was assessed on 
the Agilent 2100 bioanalyser with RNA 6000 Nano chips (Agilent). 
RNA material was amplified, transformed to cDNA and labelled 
using the Ambion WT expression kit (Ambion) and the Affyme-
trix terminal labelling kit (Affymetrix, USA). Labelled cDNA was 
then hybridised for 17 h at 42   °   C to a human ST 1.0 exon array, 
washed and stained according to manufacturer’s instructions, and 
scanned on a Genechip ® scanner 3000 (Affymetrix). Affymetrix ® 
CEL files from microarray scans were used for quality control and 
first robust multiarray averaging analysis for normalisation was 
performed with Affymetrix Expression Console. Data were pro-
cessed using ArrayStar (DNASTAR, USA). Differential expression 
tests were performed with a moderated t test implemented in 
 ArrayStar, followed by false discovery rate correction of the p val-
ues (q values) according to the method of Storey and Tibshirani 
 [20] . A gene was considered to be differentially expressed when an 
expression ratio of >4 or <–4 relative to the control was obtained. 
Differentially expressed genes were mapped to Gene Ontology 
terms to enrich for gene class using the GeneMANIA online tool 
Table 1.  Bacterial ligands used
Bacterial ligand Cognate pattern
recognition receptor
Concentration Company
Lipoteichoic acid TLR2/6 10 μg/ml Invivogen, USA
P3C TRL2/1 10 μg/ml EMC Microcollections, Germany
High-molecular-weight polyI:C TLR3 10 μg/ml Invivogen, USA
LPS (Escherichia coli serotype 0111:B4) TLR4 1 ng/ml Invivogen, USA
Flagellin (FLA-ST Ultrapure) TLR5/NLRC4 100 ng/ml Invivogen, USA
CpG (ODN 2336) TLR9 1 μg/ml Invivogen, USA
Muramyl dipeptide NOD2 5 μg/ml Sigma-Aldrich, USA
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 [21] . The proportional Venn diagram was drawn using the 
 eulerAPE application version 2.0.3  [22, 23] . Affymetrix exon array 
data are available at the Gene Expression Omnibus (GSE41295). 
 Cytokine Production  
 Levels of cytokines produced by macrophages were measured 
using the relevant human ELISA kits (Sanquin, The Netherlands) 
according to the manufacturer’s guidelines.  
 Viral Production 
 Virus titres in the culture supernatant at different time points 
after IAV infection of MDMs was determined by titration of the 
supernatant on MDCK cells and enumeration of infected MDCK 
cells. Confluent MDCK cells were infected with twofold viral dilu-
tions in DMEM with trypsin that was treated with 0.2 μg/ml L -
1-tosylamido-2-phenylethyl chloromethyl ketone (Worthington, 
USA) for 1 h at 37   °   C. After 1 h, fresh DMEM and 10% FCS were 
added and cells were incubated at 37  °  C for 16 h. Infected (GFP+) 
cells were visualised by an Olympus CKX41 microscope and virus 
titre was determined by counting the wells with  ≥ 10 and  ≤ 100 in-
fected cells/view where each data point was the average of an ex-
perimental duplicate.
 Antigen Presentation  
 MDMs were isolated and differentiated from HLA-A2+ human 
PBMCs obtained from buffy coats of healthy donors (Australian Red 
Cross). MDMs were stimulated and infected with IAV essentially as 
described above. CD8+ T cells specific to the Epstein-Barr virus 
(EBV) peptide EBV-BMLF1 280–288 (GLCTLVAML; GLC)  [24] were 
in vitro amplified by co-incubation with autologous PBMCs pulsed 
for 1 h with 10 μ M GLC. In order to augment the number of EBV-
specific T cells, T cell cultures were further amplified 7 days later by 
co-incubation for another 7 days with CIR cells that were transfect-
ed with HLA-A2, pulsed for 1 h with GLC (10 μ M ) and then irradi-
ated. The ability of infected/stimulated MDMs to present GLC to 
autologous, EBV-specific CD8+ T cells was then assessed by flow 
cytometry. Briefly, MDMs were pulsed with GLC (10  μ M ) for 90 
min. Alternatively, MDMs were pulsed with 10 μ M NS3 1073–1081 
CINGVCWTV (CING), a peptide derived from hepatitis C virus 
 [25] , as a control to confirm the specificity of the T cells. MDMs were 
then co-incubated with EBV-specific T cells for 6 h in the presence 
of FITC-conjugated anti-CD107a (eBioscience, Australia), monen-
sin (5 μ M ; Sigma, Australia) and BD GolgiPlug (BD Biosciences) 
 [26] . CD8+ T cells were then stained for CD3 (PE-Cy7; eBioscience) 
and CD8 (PerCP-Cy5.5; BD Pharmingen, USA). Cells were subse-
quently washed, fixed and permeabilised using the Cytofix/ 
Cytoperm Fixation/Permeabilisation kit (BD Biosciences) and 
stained with anti-IFN-γ (PE; BD Pharmingen). Cells were then ana-
lysed on a FACSCantoII with FACSDiva software (BD Biosciences). 
Collected samples were analysed with FLOWJO, version 8.8.7 
(TreeStar) where the percentage of single cell, CD8+ CD3+ lympho-
cytes that were either IFN-γ or CD107a positive was determined. 
 Results 
 LPS Inhibits IAV Infection of Human MDMs  
 The nasal cavity contains a variety of different leuco-
cytes situated both between surface epithelial cells and in 
the sub-epithelial layer  [10] . These leucocytes may be ex-
posed to soluble bacterial ligands either directly or fol-
lowing a breach of the epithelial basement membrane. 
Due to their longevity and crucial role in tissue homeo-
stasis  [12] , stimulation and infection of macrophages is 
of particular relevance. In order to assess the role of bac-
terial ligands in modulating IAV pathogenesis in human 
macrophages, macrophages were differentiated from the 
monocytes of healthy donors. MDMs were then stimu-
lated with select bacterial ligands for 24 h and infected 
with IAV. MDMs were also stimulated with polyinosin-
ic-polycytidylic acid (polyI:C; a TLR3/RIG-I/MDA-5 ag-
onist), a synthetic analogue of dsRNA which triggers 
type I IFN production in macrophages  [27] . As type I 
IFNs can inhibit IAV infection of leucocytes  [28, 29] , we 
reasoned that macrophages pre-stimulated with polyI:C 
would display reduced IAV infection. As expected, 
polyI:C treatment resulted in a significant decrease in 
IAV infection (p > 0.001). However, LPS pre-stimulation 
also significantly reduced IAV infection of MDMs (p < 
0.001) whilst pre-stimulation with P3C (P3C; TLR2/1 ag-
onist), lipoteichoic acid (TLR2/6 agonist), flagellin 
(TLR5/NLRC4 agonist), CpG (a TLR9 agonist) or mur-
amyl dipeptide (NOD2 agonist) did not (p > 0.05;  fig. 1 a). 
This was not due to an increased rate of macrophage 
apoptosis following LPS stimulation (data not shown) or 
differential production of IL-6, IL-10 and TNFα (online 
suppl. fig. S2; for all online suppl. material, see www.
karger.com/doi/10.1159/000353905) following stimula-
tion with LPS. 
 We then assessed whether LPS-induced inhibition of 
infection was limited to IAV, or if a similar phenotype 
was observed in response to infection with respiratory 
syncytial virus (RSV), another enveloped, negative-sense 
RNA virus. As observed with IAV, pre-stimulation with 
LPS significantly reduced rgRSV30 infection of human 
MDMs (p < 0.06;  fig. 1 b). LPS-induced inhibition of in-
fection was not restricted to GFP-labelled virus strains, as 
LPS pre-stimulation also inhibited infection of MDMs 
with the non-labelled IAV strain HKx31 (H3N2; p < 0.01; 
 fig. 1 c). These data suggest that LPS-induced inhibition 
of infection is not restricted to one IAV strain and may 
represent a more generalised mechanism of inhibiting in-
fection with enveloped, negative-sense RNA viruses. 
 To further understand the mechanism by which LPS 
inhibits IAV infection of MDMs, the kinetics of this in-
teraction was investigated. Co-administration of IAV 
and LPS (i.e. a pre-stimulation period of 0 h) did not af-
fect the rate of IAV infection ( fig. 1 d). Instead, a mini-
mum 4-hour pre-stimulation with LPS (prior to infec-
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tion with IAV) was necessary to significantly reduce the 
rate of viral infection ( fig. 1 d). The rate of IAV infection 
was inversely proportional to the time of LPS pre-stimu-
lation, such that a 24-hour pre-stimulation period had 
the greatest effect on IAV infection ( fig.  1 d). Interest-
ingly, the kinetics of polyI:C-induced viral inhibition 
were virtually identical to those observed for LPS, and the 
greatest inhibition of IAV infection occurred when the 
macrophages were pre-stimulated with polyI:C for 24 h 
( fig. 1 d). 
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 Fig. 1. Pre-stimulation with LPS inhibits IAV (GFP-PR8/34) in-
fection of human MDMs. All data sets were normalised to cells 
treated with mock infection and IAV, which were defined as 
100% infection. Accordingly, an infection rate of >100% indicates 
enhanced infection rates relative to cells treated with mock infec-
tion and IAV.  a The percentage of MDMs infected with IAV 
(MOI 0.01) 16 h after infection. Cells were stimulated with the 
relevant ligands for 24 h prior to IAV infection.  b The percentage 
of MDMs infected with RSV (MOI 1) 16 h after infection. Cells 
were stimulated with the relevant ligands for 24 h prior to RSV 
infection.  c  The percentage of MDMs infected with IAV (HKx31; 
MOI 0.1) 16 h after infection. Cells were stimulated with LPS or 
mock stimulated for 24 h prior to IAV infection.  a–c Statistical 
significance was assessed relative to ‘mock + virus’ cells using 
one-way ANOVA with Dunnet’s post hoc test ( *  p < 0.05,  * *  p < 
0.01,  * * *  p < 0.001). All data sets were normalised to cells treated 
with mock + IAV, which were defined as 100% infection. A 
dashed line indicates an infection rate of 100% (i.e. no change). 
Data are pooled from a minimum of 3 different donors.  d The 
percentage of MDMs infected with IAV (MOI 0.01) 16 h after 
infection. Cells were stimulated with LPS or polyI:C for the indi-
cated time points prior to IAV infection. A dashed line indicates 
an infection rate of 100% (i.e. no change). Data are pooled from 
3 different donors. The raw (i.e. not normalised) data are shown 
in online supplementary figure S1. LTA = Lipoteichoic acid; 
MDP = muramyl dipeptide. 
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 LPS Reduces IAV Transcription  
 There are multiple steps in the IAV replication cycle 
that LPS may inhibit. As we have measured viral infection 
by GFP expression (i.e. the production of viral proteins), 
LPS is likely to inhibit protein production or a process 
upstream of this in the viral replication cycle rather than 
a downstream process such as viral assembly or budding. 
To address how LPS inhibits IAV infection of MDMs, we 
investigated the effect of LPS pre-stimulation on the first 
stage of viral replication, i.e. adhesion to the cell surface. 
No significant difference was observed in virus adherence 
to MDMs stimulated with LPS or without stimulation for 
24 h (p > 0.05;  fig. 2 a). We then investigated the next stage 
in the IAV replication cycle, internalisation of virus par-
ticles. To measure the rate of virus internalisation, the 
number of virus particles remaining on the cell surface of 
LPS- or mock-stimulated MDMs was determined follow-
ing different incubation periods at 37  °  C. The rate of virus 
internalisation was not significantly different between 
LPS- and mock-stimulated macrophages (p > 0.05; 
 fig.  2 b). We then investigated the effect of LPS further 
downstream in the viral replication cycle by assessing vi-
ral transcription. ‘Mock- + IAV-’treated MDMs had sig-
nificantly higher levels of vRNA (p < 0.001) and mRNA 
(p < 0.05) compared to LPS-stimulated, IAV-infected 
MDMs ( fig. 2 c). These data suggest that LPS pre-treat-
ment of human MDMs inhibits viral transcription rather 
than viral attachment or internalisation. 
 LPS Induces an Antiviral State in Human 
Macrophages 
 PolyI:C pre-stimulation inhibits IAV infection of hu-
man leucocytes via triggering the production of type I 
IFNs and activating an anti-viral state in the cells  [28, 29] . 
Given that the kinetics of LPS-induced inhibition of in-
fection closely mirrored those of polyI:C, we reasoned 
that pre-stimulation with LPS also triggered an anti-viral 
state in the MDMs. A component of this anti-viral re-
sponse may then serve to reduce viral transcription. To 
further elucidate the response of MDMs to LPS, a whole-
genome array was performed on MDMs 4 h after LPS/
polyI:C/P3C stimulation. This time point was selected as 
4 h represent the minimum pre-stimulation time neces-
sary to inhibit IAV infection ( fig. 1 d). P3C (which signals 
via TLR2 and MyD88) was included in this analysis to 
represent a treatment condition that did not inhibit IAV 
infection, whilst polyI:C (which signals via TLR3 and 
TRIF) was included to represent a treatment condition 
that, like LPS, also inhibited IAV infection. Gene expres-
sion was analysed relative to mock-stimulated MDMs 
and 27 genes were identified as being  ≥ 4-fold up-regulat-
ed in LPS and polyI:C pre-stimulated macrophages, but 
not P3C pre-stimulated macrophages ( fig. 3 a; online sup-
pl. table S1). These differentially expressed genes were 
strongly associated with anti-viral/type I IFN responses 
( fig. 3 b) and included a variety of IFN-induced proteins 
(e.g. IFIT1), ‘viral-sensing’ molecules (such as RIG-I) and 
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 Fig. 2. Pre-stimulation with LPS reduces the transcription of IAV 
in human MDMs.  a The percentage of cell-surface-associated IAV 
on mock- or LPS-stimulated human MDMs following a 1-hour 
incubation at 4  °  C. Data are expressed as the percentage of cells that 
stained positive for IAV. Statistical significance between LPS- and 
mock-stimulated cells at each virus concentration was assessed us-
ing a Mann-Whitney U test.  b The percentage of cell-surface-as-
sociated IAV on mock- or LPS-stimulated human MDMs follow-
ing incubation for varying periods at 37  °  C. Data are normalised to 
mock- or LPS-stimulated MDMs held at 4   °   C for 60 min, which 
was defined as 100%. Statistical significance between LPS- and 
mock-stimulated cells was assessed using two-way ANOVA. 
 c  Copy number of vRNA and mRNA in human MDMs. Data show 
means ± SEM. Data were obtained 16 h after IAV (MOI 0.01) or 
mock infection. Copy number is expressed per 0.2 μg of RNA. All 
data were pooled from 3 different donors. Statistical significance 
was assessed by one-way ANOVA with Bonferroni post hoc cor-
rection ( *  p < 0.05,  * * *  p < 0.001). 
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anti-viral proteins (e.g. Mx1 and 2 ′ ,5′-oligoadenylate syn-
thetase 2; online suppl. table S1). Despite the fact that the 
kinetics of LPS- and polyI:C-induced inhibition of viral 
infection were identical, it remains possible that these 
TLR ligands are acting through different pathways to in-
hibit IAV infection. We therefore analysed the 66 genes 
that were specifically up-regulated only by LPS but not 
P3C or polyI:C ( fig.  3 c; online suppl. table S2). These 
genes were also strongly associated with a type I IFN re-
sponse and the inhibition of viral replication ( fig. 3 c). The 
expression of anti-viral/IFN-associated genes (including 
IFN-β, RIG-I and IFIT1) following LPS pre-stimulation 
of MDMs was subsequently confirmed by quantitative 
PCR ( fig. 3 d). Taken together, these data suggest that LPS 
may inhibit IAV infection by inducing an IFN/anti-viral 
state in human MDMs. 
 Infection of Human MDMs Is Abortive 
 We then sought to investigate the functional conse-
quences of LPS-suppressed viral infection of MDMs. In 
this study, IAV infection has been measured by GFP ex-
pression, i.e. at the level of viral protein production. There 
is currently contradicting evidence as to whether IAV in-
fection of MDMs is abortive or productive  [30] . We thus 
investigated whether LPS pre-stimulation resulted in a 
reduced number of infectious virus particles being pro-
duced in the supernatant. However, IAV infection of 
MDMs was abortive both with and without pre-stimula-
tion with LPS ( fig.  4 a). Thus, LPS pre-stimulation of 
MDMs does not affect the rate of infectious virion pro-
duction. 
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 Fig. 3. LPS induces an anti-viral state in human MDMs.  a Number 
of genes that are  ≥ 4-fold differentially expressed after stimulation 
of MDMs with LPS, polyI:C or P3C for 4 h compared to mock-
stimulated MDMs. The Euler diagram was made using eulerAPE. 
Transcription analysis was performed on MDMs from 4 different 
donors using Affymetrix human ST 1.0 exon arrays.  b Pathway 
analysis of the 27 genes up-regulated by LPS and polyI:C but not 
P3C. Analysis was performed using the online GeneMANIA. Ra-
tios were calculated by dividing the number of up-regulated 
genes associated with a specific pathway by the number of total 
genes associated with this pathway.  c Pathway analysis of the 66 
genes up-regulated by LPS but not polyI:C or P3C. Analysis was 
performed using the online software GeneMANIA. Ratios were 
calculated by dividing the number of up-regulated genes associ-
ated with a specific pathway by the number of total genes associ-
ated with this pathway.  d Fold up-regulation of IFN-β, IFN-γ, 
RIG-I, TNF-α and IFIT1 after 4 h of stimulation of MDMs with 
LPS, polyI:C or P3C. Fold up-regulation was compared to medi-
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Data represent the mean ± SEM. Data were pooled from 4 different 
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 LPS Stimulation prior to IAV Infection Decreases 
Antigen Presentation to CD8+ T Cells 
 Whilst MDMs in this study were unable to produce 
infectious virus particles, the reduced production of viral 
proteins in LPS-stimulated MDMs may affect their func-
tionality. Macrophages in IAV-infected lungs can act as 
APCs and trigger cytolysis and cytokine production by 
effector CD8+ T cells  [31] . Thus, we reasoned that de-
creased production of viral proteins in mock-stimulated 
MDMs may alter antigen presentation to CD8+ T cells. 
To assess this hypothesis, MDMs were differentiated 
from the monocytes of healthy donors. CD8+ T cells spe-
cific to the EBV-derived peptide GLC were also in vitro 
amplified from autologous PBMCs. In these experiments, 
the EBV peptide GLC was used as a model antigen to as-
sess antigen presentation. An IAV epitope was not used 
for these experiments as we wished to assess antigen pre-
sentation by IAV-infected MDMs. Hence, if an IAV an-
tigen were used, it would be difficult to differentiate the 
presentation of the externally added peptide from any 
peptides derived from the viral infection itself. The abil-
ity of LPS- or mock-stimulated MDMs to present antigen 
following IAV infection was then determined by assess-
ing the percentage of CD8+ T cells expressing the degran-
ulation marker CD107a or producing IFN-γ  [26] . MDMs 
pre-stimulated with LPS and subsequently infected with 
b
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 Fig. 4. IAV infection increases antigen presentation by human 
MDMs.  a IAV particles in the supernatant of MDMs (±LPS stim-
ulation) at various time points after IAV infection (MOI 0.01). 
Data represent the mean ± SEM and statistical significance was 
determined by two-way ANOVA. Data were pooled from 3 dif-
ferent donors.  b Representative FACS plots showing CD107a 
and IFN-γ expression by CD8+CD3+ T cells following co-incu-
bation with MDMs. Data are expressed as the percentage of 
CD107a+ or IFN-γ+ cells among CD8+CD3+ cells. Data are rep-
resentative of 3 different donors.  c The percentage of CD8+CD3+ 
cells which were positive for CD107a. All data sets were nor-
malised to cells treated with mock + IAV, which were defined as 
100% CD107a expression. Data are pooled from a minimum of 
3 different donors. Statistical significance was assessed by one-
way ANOVA with Bonferroni post hoc correction ( * *  p < 0.01, 
 * * *  p < 0.001). 
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IAV induced significantly less T cell degranulation com-
pared to unstimulated MDMs infected with IAV (p < 
0.01;  fig. 4 b, c). A similar trend in IFN-γ production by 
CD8+ T cells was also observed ( fig. 4 b). The specificity 
of this response was confirmed by the negligible CD8+ T 
cell degranulation and IFN-γ production induced by 
MDMs pulsed with an irrelevant peptide (online suppl. 
fig.  S3). Interestingly, uninfected MDMs (±LPS pre-stim-
ulated) pulsed with GLC induced less T cell degranula-
tion and IFN-γ production compared to IAV-infected 
MDMs (±LPS pre-stimulation; p < 0.001;  fig.  4 b–d). 
Thus, these data suggest that increased IAV infection of 
human MDMs results in increased antigen presentation 
to autologous CD8+ T cells.
 Discussion 
 The nasal cavity is an area of high bacterial density and 
diversity that contains both Gram-positive (e.g.  Strepto-
coccus spp.) and Gram-negative (e.g.  Haemophilus influ-
enzae and Moraxella catarrhalis ) bacteria  [32] . The nasal 
cavity is also the first site of infection for IAV. There is 
now a growing body of evidence to suggest that exposure 
to bacterial ligands, such as those in the nasal cavity, can 
affect IAV infection and disease  [6–9] . However, the ma-
jority of these studies have been performed using murine 
models of disease, and their applicability to human infec-
tions has been unclear  [6–9] . Moreover, whilst the effect 
of TLR pre-stimulation on IAV infection of epithelial 
cells has been examined  [9] , to the best of our knowledge 
this represents the first study to address the interactions 
between IAV, bacterial PAMPs and primary human 
MDMs. The ability of IAV to infect human macrophages 
has important consequences for the pathogenesis of the 
virus and the subsequent development of an adaptive im-
mune response  [30] . How this is altered following prim-
ing by soluble bacterial ligands is therefore of consider-
able interest. 
 Here, we demonstrated that pre-stimulation of hu-
man MDMs with LPS significantly impaired IAV infec-
tion of these cells. Transcriptional analysis suggested that 
this inhibition was associated with the strong anti-viral/
IFN response triggered following LPS stimulation. Al-
though the ability of LPS to elicit an IFN response in hu-
man MDMs has previously been demonstrated  [9] , this 
article represents the first evidence that this has impor-
tant consequences for IAV infection. This anti-viral re-
sponse is most likely mediated by an MyD88-indepen-
dent, TRIF-dependent signalling cascade elicited follow-
ing engagement of TLR4, which ultimately results in the 
activation of IFN regulatory factor 3 and the transcrip-
tion of IFN-β and type I IFN-inducible genes  [33, 34] . 
Unfortunately, attempts to block the IFN response in-
duced by LPS by knocking down IFN regulatory factor 3 
were unsuccessful (data not shown). This is most likely 
due to the redundancies present in the type I IFN path-
way (e.g. IFN regulatory factor 7 can also induce an IFN 
response) and the intrinsic difficulties of using siRNAs 
to inhibit antiviral responses  [35] in primary human 
cells. The role of a MyD88-independent but TRIF-de-
pendent signalling pathway in inhibiting IAV infection 
of MDMs is supported by our observation that pre-stim-
ulation with polyI:C (MyD88 independent) inhibited 
IAV infection, whilst P3C pre-stimulation (MyD88 de-
pendent) did not. It is interesting to speculate which 
components of the LPS-induced inflammatory response 
may inhibit IAV infection. One possibility is that the up-
regulation of RNase L and 2 ′ ,5 ′ -oligoadenylate synthe-
tase 1 following LPS stimulation may serve to inhibit vi-
ral transcription by degrading viral mRNA  [36] . Interest-
ingly, the inhibitory effects of proteins such as RNAse L 
on viral replication are not restricted to IAV and also 
limit the replication of a variety of other viral pathogens 
 [36] . This may explain why the phenotype observed here 
was not restricted to IAV and that LPS pre-stimulation 
also inhibited RSV infection of MDMs. The relatively 
non-specific nature of LPS-induced viral inhibition is 
further supported by previous studies showing that LPS 
stimulation of human MDMs inhibits HIV-1 infection 
 [37] . 
 A likely consequence of the reduced viral protein syn-
thesis observed in LPS-stimulated, IAV-infected macro-
phages is a decreased number of new virions being pro-
duced from infected cells. However, consistent with pre-
vious reports  [38] , we found that infection of MDMs 
with  IAV was abortive and that no new virus particles 
were produced from either mock- or LPS-pre-stimulated 
MDMs. Nevertheless, we reasoned that the high rate of 
viral infection in unstimulated MDMs was still relevant 
to the in vivo  situation as it may affect macrophage func-
tionality. Due to the longevity of macrophages, a defect in 
macrophage function is likely to have long-term conse-
quences for the immune response of the host  [39] . Whilst 
DCs are considered the most ‘professional’ APCs, one 
important function of macrophages is to present antigen 
to specific CD8+ T cells  [31] . Here, we have provided, to 
the best of our knowledge, the first evidence that IAV in-
fection affects antigen presentation by human MDMs. 
Previous studies investigating the effects of IAV on anti-
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gen presentation have largely focused on DCs. Moltedo 
et al.  [40] demonstrated that the high rate of IAV infec-
tion of CD103+ DCs (which was due to an impairment in 
type I IFN signalling) results in increased antigen presen-
tation to CD8+ T cells. Conversely, others have shown 
that primary human DCs are less able to present antigen 
to CD8+ T cells following infection with IAV  [41] . Simi-
larly, in the absence of bacterial flora mice are more sus-
ceptible to IAV infection and display reduced macro-
phage MHC-I expression and CD8+ T cell activation  [7] . 
In our experiments, the EBV peptide GLC was used as a 
model antigen to assess antigen presentation by IAV-in-
fected MDMs. This enabled us to directly assess antigen 
presentation independent of antigen processing. We 
elected not to use an IAV-derived antigen for these ex-
periments as it would be difficult to differentiate the pre-
sentation of the externally added IAV peptide from any 
peptides derived from the viral infection itself. Thus, if an 
IAV-derived antigen had been used the results would 
have been confounded by the amount of available anti-
gen, and the level of antigen processing in IAV-infected 
macrophages. 
 We demonstrated that MDMs treated with LPS and 
IAV induce less degranulation by autologous CD8+ T 
cells compared to MDMs treated with IAV alone. It is in-
teresting to note that in all experiments there was a high-
er proportion of CD107a+ CD8+ T cells than IFN-γ+ 
CD8+ T cells. This is consistent with the two distinct ac-
tivation thresholds proposed for CD8+ T cells, whereby 
only in the presence of a mature immunological synapse 
CD8+ T cells can progress from degranulation (i.e. 
CD107a positive) to cytokine production  [42] . However, 
more importantly, given the correlation observed be-
tween the rate of IAV infection in MDM and CD8+ T cell 
activation (where increasing the rate of IAV infection in-
creased the amount of CD8+ T cell activation), our data 
would suggest that infection with IAV increases antigen 
presentation by human MDMs. At present, it remains un-
clear how an increased rate of IAV infection facilitates 
increased antigen presentation. Whilst IAV infection in-
creases MHC-I expression on human DCs  [41] , we were 
unable to find any significant differences in MHC-I ex-
pression between infected and uninfected MDMs (data 
not shown). Nevertheless, our data provide the first evi-
dence that priming of primary human macrophages by 
LPS not only reduces IAV infection, but also affects anti-
gen presentation by macrophages to autologous CD8+ T 
cells. It remains possible that there are additional func-
tional consequences of increased IAV replication in mac-
rophages aside from those assessed in this study. For ex-
ample, IAV infection is known to affect macrophage 
phagocytosis  [43] , thus it is possible that whilst capable of 
increased antigen presentation, unstimulated macro-
phages may be less adept at controlling bacterial patho-
gens following IAV infection. Alternatively, the type I 
IFNs induced by LPS pre-stimulation may also influence 
the immune response to other viral infections in vivo. 
These additional functional consequences remain an area 
of ongoing research. Nevertheless, this study demon-
strates that the microbial context in which viral infections 
occur can determine the fate of infection through modu-
lation of immune effector functions.
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